Image

Leucine Supplementation Strategies to Enhance Muscle Anabolic Responses in Older Age

Leucine Supplementation Strategies to Enhance Muscle Anabolic Responses in Older Age

Recruiting
65-75 years
Male
Phase N/A

Powered by AI

Overview

Sarcopenia describes the progressive decline of muscle mass and strength with advancing age and is associated with increased frailty and morbidity, however we do not currently have an effective treatment. Protein feeding and exercise is known to increase muscle mass, but aged muscle shows a lower response to these stimuli leading to muscle loss over time. We do know that ingesting leucine, a building block of protein, can overcome this reduced response to protein feeding and exercise leading to increased muscle mass in older people. However, we do not understand when the optimum time to ingest leucine is to maximise muscle mass after exercise in older people. In this study we will examine the effect of feeding leucine after exercise either with a meal or between meals.

Eligibility

Inclusion Criteria:

  • Male, 65-75 years of age
  • BMI 18-28 kg/m2
  • Non smoker
  • Not performing regular resistance type exercise
  • Participant is willing and able to give informed consent for participation in the study

Exclusion Criteria:

  • A BMI <18 or >28 kg·m-2
  • Active cardiovascular disease: uncontrolled hypertension (BP > 160/100), angina, heart failure (class III/IV), arrhythmia, right to left cardiac shunt or recent cardiac event
  • Cerebrovascular disease: previous stroke, aneurysm (large vessel or intracranial)
  • Respiratory disease including pulmonary hypertension or chronic obstructive pulmonary disease (COPD)
  • Metabolic disease: hyper and hypo parathyroidism, untreated hyper and hypothyroidism, Cushing's disease, types 1 or 2 diabetes (treated and untreated), inborn/ congenital errors of metabolism (e.g. phenylketonuria (PKU), galactosaemia)
  • Active inflammatory bowel disease
  • Acute infection
  • Acute or chronic renal disease
  • Malignancy (or history of malignancy with 5 y)
  • Recent steroid treatment (within 6 mo), or hormone replacement therapy
  • Coagulopathy
  • Musculoskeletal or neurological disorders
  • Known allergies to any of the product ingredients
  • Having taken part in a research study in the last 3 months involving invasive procedures or an inconvenience allowance

Study details
    Muscle Protein Synthesis

NCT06567665

University of Nottingham

27 August 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.